[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cystectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cystectomy":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,54,79,108,134,165,185,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":36,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100592679","phase-2-exploring-the-impact-of-genetic-variations-on-the-clinical-efficacy-of-nalbuphine-in-postoperative-pain-management-100592679",false,"NCT06996561","Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management","Nal","Inclusion Criteria:\n\n1. All adult men or women\n2. Age 18 to 70 years\n3. ASA criteria 1,2 and 3\n4. Abdomino-pelvic surgeries (open hernia repair, appendicectomy, open cholecystectomy, laparotomy, hysterectomy, cystectomy) lasting 2-4 hours\n\nExclusion Criteria:\n\n1. Surgical procedure duration lasting more than 4 hours\n2. Patients taking anti fungal fluconazole, anticoagulant (Warfarin or Clopidogrel) SNRI (Amitryptalline), Rifampicin or Buprenorphine,\n3. History of hypersensitivity or allergy to opioids,\n4. Pregnant or breastfeeding mothers,\n5. History of narcotic dependency, addiction, and withdrawal\n6. Patients experiencing any adverse side effects or complications during surgical procedure requiring intensive care admission\n7. Refusing to participate in the study\n8. Surgical procedures utilizing other modes of intraoperative analgesia e.g epidural analgesia or nerve blocks","ALL","18 Years","70 Years",{"count":20,"type":21},263,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The goal of this study is to identify the genes as well as their association with Nalbuphine. This will help the investigator to identify opioid vulnerability in Pakistani population in the postoperative patients and will contribute to overcoming the opioid crisis, resulting in better and safer outcomes.\n\nResearch question is:\n\nIs there any association between the underlying genetic variations and the analgesic efficacy of Nalbuphine in postoperative patients? The Research Objectives are\n\n1. To identify the underlying genes in postoperative patients having pain.\n2. To find an association between identified genes and nalbuphine clinical efficacy.\n\nProcedure: After the written informed consent adult men and women will be enrolled in the study. On the day of surgery in the preoperative area, a 5 ml blood sample will be drawn before surgery and will be sent to laboratory for analysis. After routine hemodynamic monitoring in the operative room, general anesthesia will be given including nalbuphine. Standard routine anesthesia monitoring will be done and maintained while monitoring heart rate, ECG, NIBP oxygen saturation, ETCO2 and temperature. Incremental analgesia will be provided whenever needed. After extubation and shifting to recovery room the 2nd sample of blood will be taken and will be sent for analysis. Pain score, nausea vomiting, sedation, requirement of analgesia will be assessed till 24 hours postoperatively.",[28,29,30,31,32,33,34,35],"Cholecystectomy","Hernia, Abdominal","Appendectomy","Open Colorectal Surgery","Laparatomy","Postoperative Pain","Hysterectomy","Cystectomy",[37,38,39,40],"genetic variations","nalbuphine","opioids","polymorphism","RECRUITING","2026-04-14",{"date":44,"type":45},"2026-04-15","ACTUAL",{"date":47,"type":45},"2025-09-01",{"date":49,"type":21},"2027-06-30",{"name":51,"class":52},"Dr. Asma Abdus Salam","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":61,"minAge":17,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":53},"100634241","lidocaine-for-less-postoperative-shoulder-pain-alleviation-100634241","NCT07537127","Lidocaine for LESS Postoperative Shoulder Pain Alleviation","Subdiaphragmatic Infiltration of Diluted Lidocaine During Single-incision Laparoscopic Surgery for Postoperative Shoulder Pain Alleviation","Inclusion Criteria:\n\n* Age: Female patients aged 18-65 years;\n* Clear preoperative diagnosis, suitable for single-port laparoscopic surgery, and American Society of Anesthesiologists (ASA) physical status classification I-II;\n* Patients or their family members can understand the study protocol, are willing to participate in the study, and provide written informed consent.\n\nExclusion Criteria:\n\n* Allergy to lidocaine or amide-type local anesthetics;\n* Severe medical comorbidities;\n* Long-term preoperative use of opioid drugs or sedatives;\n* Pregnant or lactating women;\n* Conversion to laparotomy or addition of surgical ports during surgery.","FEMALE","65 Years",{"count":64,"type":21},100,[66],"NA","Objective: To evaluate the efficacy of subdiaphragmatic spray of 0.08% lidocaine in relieving postoperative acute pain and psychological status of patients undergoing single-port laparoscopic surgery for benign gynecological diseases, and to provide evidence-based basis for optimizing postoperative analgesic strategies.\n\nMethods: A single-center, prospective randomized controlled study was conducted. A total of 100 patients scheduled for elective single-port laparoscopic surgery due to uterine fibroids, ovarian cysts, or other benign gynecological conditions were selected from the General Gynecology Center of Peking Union Medical College Hospital. They were divided into the experimental group (n=50) and the control group (n=50) using a random number table. The experimental group received 50 ml of 0.08% lidocaine solution sprayed on the bilateral subdiaphragmatic regions at the start of surgery, while the control group underwent standard ERAS without any pharmaceutical intervention in the subdiaphragmatic area. The primary endpoint was the Numerical Rating Scale (NRS) score for resting pain at 6 hours postoperatively. The secondary endpoints included NRS scores at 1, 2, 12, and 24 hours postoperatively, total consumption of analgesics within 48 hours after surgery, incidence of adverse reactions, patient satisfaction, and scores of psychological and sleep scales (Distress Thermometer, GAD-7, etc.) at 30 days postoperatively. SPSS 25.0 software was used for data analysis. Quantitative data were analyzed by t-test or Mann-Whitney U test, and qualitative data were analyzed by χ² test or Fisher's exact test. Repeated measurement data were analyzed by repeated measures analysis of variance.\n\nResults: After the completion of the study, differences in NRS scores, analgesic consumption, psychological status and other indicators between the two groups will be compared.\n\nConclusion: The results of this study will clarify the clinical value of intraoperative diaphragmatic infiltration with low-concentration lidocaine in postoperative analgesia after single-port laparoscopic gynecological surgery, and provide references for postoperative pain management and psychological intervention.",[35,69],"Myomectomy","2026-04-12",{"date":72,"type":45},"2026-04-17",{"date":74,"type":45},"2025-12-15",{"date":76,"type":21},"2026-08-14",{"name":78,"class":52},"Peking Union Medical College Hospital",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100610255","home-intravenous-fluid-infusion-after-undergoing-radical-cystectomy-100610255","NCT07225205","Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy","Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients greater than 18 years of age and older\n* Confirmed urothelial carcinoma on pathology, including muscle invasive, non-muscle invasive, and variant histology\n* Patient electing to undergo radical cystectomy with bilateral pelvic lymphadenectomy after counseling with a urologic oncologist.\n\nExclusion Criteria:\n\n* Patients undergoing radical cystectomy for benign indications (e.g. chronic bladder pain, fistulas, severe lower urinary tract symptoms)\n* Patients undergoing radical cystectomy for a non-bladder primary malignancy (e.g. rectal, colon, uterine cancers).\n* Patients with extensive locally advanced disease necessitating a pelvic exenteration\n* Contraindication to receiving home IVF therapy (i.e. pre-existing cardiac, renal, hepatic dysfunction)\n* Unwilling or unable to participate in 30 and 90 day follow-up phone calls.",{"count":87,"type":21},130,[66],"Radical cystectomy is the standard of care for muscle invasive bladder cancer, however despite advances, it is still associated with high morbidity. Many complications may be driven by dehydration and it is unclear if a home intravenous fluid (IVF) infusion program post-operatively, which is an accepted standard practice, is beneficial. This study is a single institution randomized controlled trial where patients who choose to undergo radical cystectomy for bladder cancer will be randomized to an Enhanced Recovery After Surgery (ERAS) protocol with a home IVF program, consisting of 1 liter (L) of crystalloid fluid three times per week for four weeks, or ERAS protocol alone. The primary outcome will be 90-day hospital re-admissions, with secondary outcomes including 30 and 90 day complications.",[91,92,93,35],"Bladder Cancer","Muscle Invasive Bladder Cancer (MIBC)","Muscle Invasive Bladder Cancer Urothelial Carcinoma",[35,91,92,95,96,97],"Fluids","IVF","ERAS","2025-11-19",{"date":100,"type":45},"2025-11-20",{"date":102,"type":45},"2025-11-01",{"date":104,"type":21},"2028-02-01",{"name":106,"class":52},"Johns Hopkins University",2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":53},"100593578","robot-assisted-cystectomies-with-regard-to-blood-loss-pain-and-transfusions-100593578","NCT07008261","Robot-assisted Cystectomies With Regard to Blood Loss, Pain and Transfusions.","Prospective Evaluation of Robot-assisted Cystectomies With Regard to Blood Loss, Pain and Transfusion Requirements.","Inclusion Criteria:\n\n* planned radical cystectomy\n\nExclusion Criteria:\n\n* ASA classification V\n* Previously known coagulation disorder",{"count":116,"type":21},60,"OBSERVATIONAL","What influence does robot-assisted surgical treatment in the sense of a radical cystectomy and possibly bladder reconstruction have on blood loss, pain and transfusion requirements? We intend to conduct a corresponding prospective observational study at a tertiary centre.",[120,35,121,122,123,124],"Transfusions","Blood Loss Requiring Transfusion","Anaemia","Anaemia Postoperative","Pain, Postoperative","2025-08-25",{"date":127,"type":45},"2025-09-02",{"date":129,"type":45},"2025-08-01",{"date":131,"type":21},"2027-12-31",{"name":133,"class":52},"Goethe University",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":146,"conditions":147,"keywords":152,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":164},"100570588","phase-4-clinical-trial-testing-whether-targeted-antibiotic-prophylaxis-can-reduce-infections-after-cystectomy-compared-to-empiric-prophylaxis-100570588","NCT06709196","Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","REINFORCE - Reducing Infection-related Readmissions Following Cystectomy. a Multicentre Randomised Clinical Trial Testing Superiority of Individualised Targeted Antibiotic Prophylaxis Over Empiric Prophylaxis At Ureteral Stent Removal to Reduce Infection-related Readmissions Following Cystectomy.","REINFORCE","Inclusion Criteria:\n\n* Age at surgery ≥ 18 years\n* Ability to understand and sign an informed consent\n* Malignant or benign indication for undergoing cystectomy\n* Planned ileal conduit as urinary diversion\n\nExclusion Criteria:\n\n* Previous severe allergic reaction to antimicrobial treatment\n* Long-term prophylactic antibiotic treatment which is expected to be continued after the cystectomy",{"count":143,"type":21},248,[145],"PHASE4","The aim of this trial is to test whether postoperative antibiotics targeted towards bacteria in the urine can reduce the risk of infection after surgical removal of the bladder (cystectomy) compared to a standardised antibiotic prophylaxis.\n\nParticipants undergoing cystectomy will be randomly assigned to postoperatively receive (A) a standardised orally administered antibiotic prophylaxis currently given at Rigshospitalet, Copenhagen or (B) a conventional orally administered antibiotic prophylaxis targeting bacteria found in the urine postoperatively.\n\nThe investigators' hypothesis is that the targeted prophylactic antibiotic strategy will reduce the number of infection-related readmissions within 90 days of surgery compared to the standardised prophylaxis.",[35,148,149,150,151],"Bladder Cancer Requiring Cystectomy","Postoperative Infections","Antibiotic Prophylaxis","Ileal Conduit",[153,154],"Targeted antimicrobial prophylaxis","Infection-related readmissions","2025-01-08",{"date":157,"type":45},"2025-01-09",{"date":159,"type":45},"2025-01-07",{"date":161,"type":21},"2027-01",{"name":163,"class":52},"Rigshospitalet, Denmark",5,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":176,"conditions":177,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":53},"100575303","phase-4-introduction-of-mycotic-prophylaxis-at-cystectomy-trial-100575303","NCT06770530","Introduction of Mycotic Prophylaxis At Cystectomy Trial.","IMPACT - the Introduction of Mycotic Prophylaxis At Cystectomy Trial. Perioperative Mycotic Prophylaxis to Reduce Postoperative Complications Following Cystectomy - a Double-blinded, Placebo-controlled, Randomized Trial","IMPACT","Inclusion Criteria:\n\n* Patients 18 years and older\n* Willingness to participate in the study and the ability to understand and sign an informed consent\n* Indication for performing cystectomy\n* The urinary diversion is limited to the ileal conduit\n\nExclusion Criteria:\n\n* Patients with contraindications to Fluconazole. This includes allergies and treatment with non-pausable medication that in combination is contraindicated\n* Patients in active treatment for mycotic infections",{"count":174,"type":21},484,[145],"This study aims to introduce a perioperative antifungal prophylaxis for patients undergoing cystectomy: surgically removal of the urinary bladder with construction of a urinary diversion. We wish to investigate the effect of antifungal prophylaxis on complications after the operation.",[35],{"date":179,"type":45},"2025-01-13",{"date":181,"type":45},"2024-06-24",{"date":183,"type":21},"2027-09",{"name":163,"class":52},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":192,"sex":61,"minAge":4,"maxAge":17,"enrollmentInfo":193,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":53},"100371617","pediatric-ovarian-tissue-banking---operative-specimens-from-females-0-18-years-of-age-100371617","NCT04118712","Pediatric Ovarian Tissue Banking - Operative Specimens From Females 0-18 Years of Age","OTB","Inclusion Criteria:\n\n* Pre and Post Pubertal females\n* Ages 0-18 years old\n* Undergoing scheduled or emergent operative procedures involving the ovary\n\n  1. oophorectomy (torsion, benign mass\u002Fcyst, malignant mass\u002Fcyst)\n  2. ovarian cystectomy\n\nExclusion Criteria:\n\n* Pregnant females",true,{"count":64,"type":21},"A child is eligible to participate in this study because she is having surgery on her ovary. The investigators may obtain a sample of any discarded tissue from the surgery for an ovarian tissue library. This study is being conducted to understand how common ovarian conditions effect the number and quality of ovarian follicles and the reproductive potential of the ovary.",[196,35,197,198],"Benign Cysts Ovarian","Torsion","Malignant Cysts Ovarian","2024-11-14",{"date":201,"type":45},"2024-11-18",{"date":203,"type":45},"2016-10-18",{"date":205,"type":21},"2030-12",{"name":207,"class":52},"Ann & Robert H Lurie Children's Hospital of Chicago",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":192,"sex":16,"minAge":17,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":107},"100494246","patient-centered-surgical-prehabilitation-100494246","NCT05715684","Patient-Centered Surgical Prehabilitation","Prehab","Inclusion Criteria:\n\n1. Patents must be candidates for all types of cystectomy surgery including urinary diversion via open or robotic approach.\n2. Patients between the ages 18 and 85 years\n3. American Society of Anesthesiologists (ASA) Physical Status Score of class 1-4\n4. Ileal conduit or ileal neobladder urinary diversion\n5. Able to understand the study procedures, agreed to participate in the study program, and voluntarily provided informed consent\n\nExclusion Criteria:\n\n1. Scheduled for a partial cystectomy\n2. Previous total colectomy, gastrectomy, or gastric bypass, or functional colostomy or ileostomy\n3. More than three doses of opioids (oral or parenteral) within 7 days before the day of surgery\n4. The presence of metastatic cancer\n5. Be undergoing treatment for another type of cancer concurrently\n6. Chemotherapy for bladder cancer within 1 month of scheduled surgery; prior neoadjuvant chemotherapy allowed.\n7. Pregnant (identified by a positive serum pregnancy test administered after the initial screening process and before the commencement of study activities) or lactating, or not postmenopausal (no menses for at least 1 year) and of childbearing potential and not using an accepted method of birth control (i.e, surgical sterilization; intrauterine contraceptive device; oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam; or abstinence) (Participants will be asked to use birth control for the entire study and for at least 2 weeks after the last dose of study drug.)\n8. Participated in another investigational drug or medical device study within 30 days of surgery or planning to be enrolled in another investigational drug or medical device study or any study in which active patient participation was required outside normal hospital data collection during the course of this study\n9. Clinically significant laboratory abnormalities at screening that would have resulted in the cancellation of surgery\n10. Using illicit drugs or abusing alcohol\n11. History of previous surgeries, illness, or behavior (eg, depression, psychosis) that in the opinion of the investigator might have confounded the study results or might have posed additional risk in administering the study procedures\n12. Patients with severe dementia (as determined from medical records and history. Severe dementia will be defined as dementia that impacts daily functioning.)\n13. Patients with severe hepatic impairment as defined by Child-Pugh Class C. Patients with Child-Pugh Class A-B hepatic impairment are eligible for the study.\n14. A history of heart failure.\n15. Patients with end-stage renal disease as defined by GFR \\\u003C15.\n16. Patients with heart failure.\n17. Patients with complete gastrointestinal obstruction.\n18. Patients with gastrostomy tube, jejunostomy tube or who require enteral tube feeds.\n19. Non-English-speaking patients","85 Years",{"count":217,"type":21},25,[66],"The purpose of this research is to validate the prehabilitation program which is defined as a set of interventions meant to prepare the body physically and nutritionally for the cystectomy procedure.",[91,35],"2023-03-20",{"date":223,"type":45},"2023-03-22",{"date":225,"type":45},"2023-03-01",{"date":227,"type":21},"2027-12-25",{"name":229,"class":52},"Dana-Farber Cancer Institute"]